#China #Suzhou #Crystal Pharmatech #ELDICO Scientific #MicroED Technology

Crystal Pharmatech Pioneers MicroED Technology in Asia-Pacific

Crystal Pharmatech, a science-driven Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), has recently made a significant advancement in the world of pharmaceutical development. On April 14, 2026, the company announced the deployment of the ELDICO ED-1 microcrystal electron diffractometer, marking it as the first company in both China and the Asia-Pacific region to implement a dedicated MicroED (Microcrystal Electron Diffraction) platform aimed specifically at industrial applications. This innovative leap is set to transform how drug development is approached globally.

A New Era of Drug Development

The ED-1 is not just another piece of laboratory equipment; it represents a paradigm shift in the methodologies used for determining crystal structures of small-molecule drugs. Traditionally, most techniques rely on modified Transmission Electron Microscopes (TEMs) for similar analyses, which are often cumbersome and dependent on specialized expertise. With the deployment of the ED-1, Crystal Pharmatech is pioneering a new pathway, integrating MicroED into routine workflows to allow for higher throughput and scalability, fundamentally enhancing the development timeline for pharmaceuticals.

The device is designed for practical applications in the pharmaceutical sector, supporting automated operation around the clock. This means that data can be acquired more efficiently and accurately, reducing the dependence on prior expert knowledge. As a result, MicroED is transitioning from being a niche, specialized technique to a mainstream tool that can be reliably used across various industrial applications.

What Makes the ED-1 Unique?

The ELDICO ED-1 is globally recognized as the first purpose-built electron diffractometer designed specifically for determining crystal structures from sub-micron crystalline powders. This groundbreaking technology is particularly invaluable for small-molecule compounds, facilitating remarkable precision in obtaining crystal structure data.

Among its features, the ED-1 allows for:

• - Direct determination of crystal structures, chirality, and absolute configuration from complex mixtures and low-crystallinity materials.
• - Comprehensive polymorph, salt, and cocrystal screening through extensive mapping of the polymorphic landscape.
• - Ultra-sensitive detection of trace polymorphic impurities, ensuring the highest quality in drug products.
• - Characterization of amorphous solid dispersions to confirm the absence of residual crystallinity in pharmaceutical systems.
• - Acceleration of preformulation and formulation processes by enabling quick, structure-driven decisions.

Strategic Partnership with ELDICO Scientific

The deployment of the ED-1 is part of an ongoing strategic collaboration with ELDICO Scientific AG, a renowned leader in structural analysis through electron diffraction. This partnership is not only strengthening Crystal Pharmatech's offerings in the realm of solid-state research but also reinforces its commitment to delivering robust analytical solutions to meet the demands of global pharmaceutical companies.

Alex Chen, Co-founder and CEO of Crystal Pharmatech, expressed his enthusiasm regarding this integration, stating, "Integrating the ELDICO ED-1 into our portfolio represents a major step toward making MicroED a routine tool in pharmaceutical development. We are driven by the aspiration to determine the crystal structure of every polymorph, and with this technology, that goal is coming within reach."

Commitment to Scientific Advancement

Since its inception in 2010, Crystal Pharmatech has been deeply rooted in solid-state research, providing expertise across the life cycle of drug development. The company has successfully supported over 2,000 clients and contributed to thousands of compounds worldwide. With the recent introduction of the ED-1 into its operational framework, Crystal Pharmatech is poised to lead advancements in scientific research, thereby enhancing drug efficacy and safety.

As commercial pressures and competition in the pharmaceutical sector continue to escalate, the ability to efficiently and effectively determine drug characteristics has never been more crucial. Crystal Pharmatech is not just keeping pace with these demands; it's setting a new standard and positioning itself at the forefront of innovation within the life sciences.

Conclusion

The deployment of the MicroED platform heralds a new era in the industrialized solid-state characterization technologies that are set to revolutionize the pharmaceutical landscape. With their continual improvements and commitments to excellence in scientific research, Crystal Pharmatech is expected to play a pivotal role in shaping the future of drug development across the globe.

For further information on Crystal Pharmatech and its offerings, visit their official website or contact their investor relations directly.